ELDN
NASDAQEledon Pharmaceuticals Inc.
Price$2.13-0.09 (-4.05%)
01:30 PM07:45 PM
News · 26 weeks30-33%
2026-04-192026-10-11
Mix1190d
- Other6(55%)
- SEC Filings3(27%)
- Insider2(18%)
Latest news
25 items- PREledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual MeetingIRVINE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced an oral presentation will be featured at the upcoming American Society of Nephrology Kidney Week 2026 Annual Meeting taking place in Denver, CO, from October 21-25, 2026. The oral presentation will highlight patient-reported outcomes from the Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in kidney transplantation. Details of the presentation are below: Title: Patient-Reported Outcomes in the Phase 2 BESTOW Trial Comparing Tegoprubart to Tacrolimus in Kidney Transplant Recipients Presenter: Andrew B. Adams, M.D., Ph.D., Department of Surger
- PREledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation SocietyTegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus tacrolimus (71 vs. 58 mL/min/1.73 m²) at month 24 No rejections occurred in the tegoprubart arm beyond six months post-transplant, compared with seven in the tacrolimus arm Tegoprubart granted U.S. FDA Fast Track designation for the prevention of rejection in kidney transplantation Phase 3 LEGACY study expected to initiate in the fourth quarter of 2026 IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced updated long-term data fro
- PREledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation SocietyIRVINE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced an oral presentation highlighting the long-term safety and efficacy of tegoprubart in preventing kidney transplant rejection will take place at the upcoming International Congress of The Transplantation Society in Sydney, Australia, from September 20–23, 2026. Details of the presentation are below: Oral Presentation Title: Phase 2 BESTOW trial and the BESTOW EXTENSION: Evaluating the long-term safety and efficacy of tegoprubart in preventing kidney transplant rejection Presenter: Andrew Adams, M.D., Ph.D., Professor of Surgery and Chief Division of Transplantation, J
- SECSEC Form S-8 filed by Eledon Pharmaceuticals Inc.S-8 - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
- PREledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026IND submitted to FDA for Eledon-sponsored, registrational study of tegoprubart in islet cell transplantation for patients with type 1 diabetes First patients enrolled in new investigator-initiated study of tegoprubart in patients with renal dysfunction receiving an islet cell transplant First patient dosed under compassionate use of tegoprubart for conversion from tacrolimus in islet cell transplant recipients with calcineurin inhibitor related kidney dysfunction First patients dosed under compassionate use of tegoprubart in highly sensitized patients with pre-existing antibodies receiving a kidney transplant Company on track to initiate global Phase 3 LEGACY trial of tegoprubart
- SECSEC Form 10-Q filed by Eledon Pharmaceuticals Inc.10-Q - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
- SECEledon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
- PREledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business HighlightsSuccessful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026 Long-term Phase 2 BESTOW data presented at ATC 2026 demonstrated sustained higher kidney function and improved patient-reported outcomes with tegoprubart compared with tacrolimus Updated islet cell transplantation data presented at ADA 2026 showed 100% insulin independence in all 12 patients with type 1 diabetes Cash, cash equivalents and short-term investments of $88.8 million as of June 30, 2026 IRVINE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its seco
- INSIDERChief Executive Officer Gros David-Alexandre C was granted 354,454 shares and covered exercise/tax liability with 194,791 shares, increasing direct ownership by 1,774% to 168,663 units (SEC Form 4) (withholding tax)4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
- INSIDERPresident Perrin Steven was granted 152,353 shares and covered exercise/tax liability with 72,138 shares, increasing direct ownership by 8,022% to 81,215 units (SEC Form 4) to cover withholding tax4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
- PRA Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating UpIssued on behalf of Avaí Bio, Inc. (OTCQB:AVAI)LAS VEGAS, July 21, 2026 /CNW/ -- (American News Group News Commentary) For the millions of people who manage diabetes with daily insulin injections, the holy grail has always been the same: a therapy that senses blood sugar and releases the right amount of insulin on its own, the way a healthy pancreas does. A growing group of biotech companies is chasing that goal with cell-based therapies, and this week one small player took a concrete step toward making its version real. The milestone is a supply deal, which may sound unglamorous, but in cell therapy the source of the cells is
- PRThe Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho TherapyIssued on behalf of Avaí Bio, Inc.As cell-based medicine moves from the lab toward the clinic across diabetes, transplant, and aging, Avaí Bio and partner Austrianova have banked the genetically modified cells that will manufacture their encapsulated alpha-Klotho productLAS VEGAS, July 8, 2026 /CNW/ -- USA News Group News Commentary - The most valuable real estate in medicine right now is a living cell. Across diabetes, organ transplant, and the fast-emerging field of longevity biology, developers are racing to turn engineered and donor-derived cells into durable, manufacturable therapies, and the companies that reach GMP-grade production first are the ones the market takes seriously. That i
- PRNewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 DiabetesZURICH, July 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, announced the successful completion of its Type B Pre-IND meeting with the U.S. Food and Drug Administration ("FDA"). The agency provided constructive feedback and alignment on the Company’s proposed development strategy, providing clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-101 for type 1 diabetes in combination with Eledon Pharmaceuticals’ (NASDAQ:ELDN) anti-CD40L antibody, tegoprubart, an investigational immunomodulatory agent. The meeting results represent a significant milestone t
- PRNatera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant TrialProspera selected as exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay for use in Eledon’s planned Phase 3 trial of tegoprubart in kidney transplantation, expected to initiate in late 2026Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN), a clinical stage biotechnology company developing immune-modulating therapies for the management and treatment of life-threatening conditions, today announced a strategic partnership to incorporate Natera’s Prospera kidney transplant assessment test into Eledon’s planned Phase 3 clinical trial of tegoprubart, an investigational therapy designed to prevent organ
- SECEledon Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
- PREledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with TacrolimusTegoprubart-treated patients maintained higher mean eGFR over time, including a statistically significant approximately 12 mL/min/1.73 m² advantage at month 18 versus tacrolimus (74 vs. 61 mL/min/1.73 m²; p<0.05) No biopsy-proven acute rejection (BPAR) events were observed in tegoprubart-treated patients after the first six months post-transplant, compared with seven BPAR events (9.4% of tacrolimus-treated patients) reported in the tacrolimus arm Patient-reported outcomes at 52 weeks favored tegoprubart, with statistically significant improvements versus tacrolimus on two validated measures of symptom burden Conference call and webcast to be held today at 8:00 a.m. ET IRVINE, Calif., Jun
- PREledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine– All 12 patients in study (100%) achieved insulin independence, producing their own insulin and no longer requiring exogenous insulin therapy to manage their T1D – All 12 patients also achieved an HbA1c below 6.5%, with a mean most recent HbA1c of approximately 5.4%, representing an approximately 2.6% average improvement in HbA1c from baseline – No severe hypoglycemic episodes were reported post-transplant, compared with a history of recurrent severe hypoglycemic events prior to transplantation in all enrolled patients IRVINE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced updated results from an investigator-initiated tr
- PREledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific SessionsIRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that updated results from an investigator-initiated trial being conducted at the University of Chicago Medicine Transplant Institute will be presented by Piotr Witkowski, M.D., Ph.D., Director of the Pancreas and Islet Transplant Program at UChicago Medicine, at the American Diabetes Association 86th Scientific Sessions, taking place June 5-9, 2026, in New Orleans, Louisiana. Details of the oral presentation are as follows: Presentation Title: Anti-CD40L to Induce Graft Survival and Function in Islet AllotransplantationSession: Immune Modulatory Strategies for Next-Gene
- PRNewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 DiabetesPre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the submission of a Pre-Investigational New Drug ("Pre-IND") briefing package to the U.S. Food and Drug Administration ("FDA") to support the proposed First-In-Human ("FIH") clinical trial of NCEL-101 in combination with tegoprubart, an investigational immunomodulatory agent being developed by Eledon Pharmaceuticals (("Eledon", NASDAQ:ELDN). The submission represents a significant mi
- PREledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant CongressIRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the Company will present new clinical data from its tegoprubart program in patients undergoing kidney transplantation in an oral and a poster presentation at the American Transplant Congress (ATC) taking place in Boston, MA from June 20-24, 2026. Results will include updated data from the Phase 2 BESTOW clinical trial and new long-term data from the Phase 2 BESTOW extension study. Details on the presentations are below: Oral Presentation Title: Phase 2 BESTOW Trial: Evaluating Tegoprubart's Safety and Efficacy in Preventing Kidney Transplant Rejection Presenter: A
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Eledon Pharmaceuticals Inc.SCHEDULE 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
- SECSEC Form 10-Q filed by Eledon Pharmaceuticals Inc.10-Q - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
- SECEledon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
- PREledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights100% insulin independence achieved in 10 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study FDA Orphan Drug designation granted to tegoprubart for the prevention of allograft rejection in liver transplantation Cash, cash equivalents and short-term investments totaled $111.1 million as of March 31, 2026 IRVINE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its first quarter 2026 operating and financial results and provided recent business highlights. "In the first quarter of 2026, we achieved significant milestones in our tegoprubart program, including impo
- SECSEC Form EFFECT filed by Eledon Pharmaceuticals Inc.EFFECT - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
ELDN FAQ
7 questionsWhat does Eledon Pharmaceuticals Inc. do?
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was...Where does ELDN stock trade?
Eledon Pharmaceuticals Inc. (ELDN) is listed on NASDAQ.What sector and industry is ELDN in?
Eledon Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Eledon Pharmaceuticals Inc. go public?
Eledon Pharmaceuticals Inc. (ELDN) completed its IPO in 2014.What are analysts saying about ELDN?
Eledon Pharmaceuticals Inc. has had 4 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $900.00 price target on 2025-06-18. Recent price targets range from $900.00 to $2500.00.What companies are similar to ELDN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ELDN side-by-side with any of them on Quantisnow.How can I track ELDN on Quantisnow?
Quantisnow aggregates Eledon Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ELDN to receive live email and push alerts on every new disclosure.